In addition to significant anti-proliferative activity in 2D and 3D in vitro pancreatic cancer cultures [119,121], FAK inhibition significantly inhibited pancreatic tumour progression in vivo in the KPC model of PDAC [15], and extended the anti-tumour response to gemcitabine and Abraxane combination in patient-derived PDAC xenograft models 121. Here, PTK2 is linked to pancreatic neoplasm.